ATLANTA, GA – – (Globe Newswire – January 14, 2025) – – A shareholder class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX). The lawsuit alleges that Defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel. The lawsuit alleges that Pacira knew that the ‘495 patent was not as protective as Defendants publicly touted.

If you bought shares of Pacira between August 2, 2023 and August 8, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/pacira-biosciences/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 14, 2025.